• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Reply to E. Hindié.致E. 欣迪埃的回复。
J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23.
2
Reply to E. Avisar, H. Kuerer, L. Livi et al, and E. Hindié et al.对E. 阿维萨尔、H. 库勒、L. 利维等人以及E. 欣迪埃等人的回复
J Clin Oncol. 2016 Aug 1;34(22):2674-5. doi: 10.1200/JCO.2016.67.6148. Epub 2016 May 23.
3
Reply to E. Hindié.
J Clin Oncol. 2021 Mar 10;39(8):944-946. doi: 10.1200/JCO.20.03463. Epub 2021 Jan 25.
4
Reply to E. Hindié.
J Clin Oncol. 2023 Aug 1;41(22):3874-3875. doi: 10.1200/JCO.23.00794. Epub 2023 May 31.
5
Reply to A. Mangla and E. Hindié.
J Clin Oncol. 2023 Feb 20;41(6):1326-1327. doi: 10.1200/JCO.22.02218. Epub 2022 Dec 1.
6
Reply to Y. Lu et al and E. Hindié et al.对Y. Lu等人及E. Hindié等人的回复
J Clin Oncol. 2022 Nov 1;40(31):3670-3671. doi: 10.1200/JCO.22.01302. Epub 2022 Jul 5.
7
Reply to E. Hindié et al.对E. 欣迪埃等人的回复
J Clin Oncol. 2019 Aug 10;37(23):2092-2093. doi: 10.1200/JCO.19.01078. Epub 2019 Jun 28.
8
Reply to E. Hindié and A.K. Goel et al.对E. 欣迪埃和A.K. 戈尔等人的回复
J Clin Oncol. 2019 Oct 10;37(29):2705-2707. doi: 10.1200/JCO.19.01860. Epub 2019 Aug 29.
9
Reply to E. Hindié and K.R. Hess.对E. 欣迪埃和K.R. 赫斯的回复。
J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2.
10
Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al.对J.A. 瓦尔戈等人、H.J.A. 亚当斯等人、E. 欣迪耶等人以及S. 科塔里等人的回复
J Clin Oncol. 2017 Aug 20;35(24):2853-2854. doi: 10.1200/JCO.2017.74.0068. Epub 2017 Jul 6.

本文引用的文献

1
Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.黑色素瘤的全身治疗:美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 Jul 20;40(21):2375-2377. doi: 10.1200/JCO.22.00944. Epub 2022 Jun 3.
2
Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim.
J Clin Oncol. 2020 Sep 20;38(27):3237-3238. doi: 10.1200/JCO.20.01199. Epub 2020 Jul 23.
3
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.影响薄型(T1)皮肤黑色素瘤前哨淋巴结转移的因素:预测列线图的开发与外部验证
J Clin Oncol. 2020 May 10;38(14):1591-1601. doi: 10.1200/JCO.19.01902. Epub 2020 Mar 13.
4
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.辅助达布拉非尼联合曲美替尼对比安慰剂治疗 BRAF 突变型 III 期黑色素瘤患者(COMBI-AD):一项随机、III 期临床试验的探索性生物标志物分析。
Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30.
5
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.AJCC-8 分期在 III 期 EORTC1325/KEYNOTE-054 试验中对帕博利珠单抗对比安慰剂治疗切除的高风险 III 期黑色素瘤的预后和预测价值。
Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.
6
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.皮肤黑色素瘤临床实践指南(第 2 版).2019,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.
7
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.黑色素瘤分期:美国癌症联合委员会第八版癌症分期手册中基于证据的变化。
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.
8
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.黑色素瘤前哨淋巴结转移的完全解剖或观察
N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.
9
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.年龄作为局限性黑色素瘤患者前哨淋巴结转移的预测因素:年轻和老年患者中黑色素瘤死亡率与前哨淋巴结转移发生率的负相关。
Ann Surg Oncol. 2014 Apr;21(4):1075-81. doi: 10.1245/s10434-013-3464-x. Epub 2014 Feb 15.
10
Melanoma sentinel node biopsy and prediction models for relapse and overall survival.黑色素瘤前哨淋巴结活检和复发及总生存预测模型。
Br J Cancer. 2010 Oct 12;103(8):1229-36. doi: 10.1038/sj.bjc.6605849. Epub 2010 Sep 21.

Reply to E. Hindié.

作者信息

Maurichi Andrea, Miceli Rosalba, Eriksson Hanna, Newton-Bishop Julia, Nsengimana Jérémie, Chan May, Hayes Andrew J, Heelan Kara, Adams David, Patuzzo Roberto, Barretta Francesco, Gallino Gianfranco, Harwood Catherine, Bergamaschi Daniele, Bennett Dorothy, Lasithiotakis Konstantinos, Ghiorzo Paola, Dalmasso Bruna, Manganoni Ausilia, Consoli Francesca, Mattavelli Ilaria, Barbieri Consuelo, Leva Andrea, Cortinovis Umberto, Espeli Vittoria, Mangas Cristina, Quaglino Pietro, Ribero Simone, Broganelli Paolo, Pellacani Giovanni, Longo Caterina, Del Forno Corrado, Borgognoni Lorenzo, Sestini Serena, Pimpinelli Nicola, Fortunato Sara, Chiarugi Alessandra, Nardini Paolo, Morittu Elena, Florita Antonio, Cossa Mara, Valeri Barbara, Milione Massimo, Pruneri Giancarlo, Zoras Odysseas, Anichini Andrea, Mortarini Roberta, Santinami Mario

机构信息

Andrea Maurichi, MD, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Rosalba Miceli, PhD, Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Hanna Eriksson, MD, PhD, Department of Oncology, Theme Cancer, Karolinska University Hospital, and Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Julia Newton-Bishop, MD, FRCP; Jérémie Nsengimana, PhD; and May Chan, PGD, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom; Andrew J. Hayes, MA, MBBS, MD, PhD and Kara Heelan, MB, BCH, BAO, MRCPI, MD, Sarcoma and Melanoma Units and Skin Unit, The Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom; David Adams, PhD, Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Roberto Patuzzo, MD, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Francesco Barretta, MS, PhD, Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Gianfranco Gallino, MD, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Catherine Harwood, MA, MD, PhD, FRCP and Daniele Bergamaschi, PhD, Queen Mary University of London, London, United Kingdom; Dorothy Bennett, FMedSci, PhD, Molecular and Clinical Sciences Research Institute, St George's, University of London, London, United Kingdom; Konstantinos Lasithiotakis, MD, PhD, York Teaching Hospital NHS Foundation Trust, York, United Kingdom and Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Paola Ghiorzo, MD, PhD and Bruna Dalmasso, MD, University Hospital of Genoa, Genoa, Italy; Ausilia Manganoni, MD and Francesca Consoli, MD, University Hospital of Brescia, Brescia, Italy; Ilaria Mattavelli, MD; Consuelo Barbieri, MD; and Andrea Leva, MD, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Umberto Cortinovis, MD, Plastic and Reconstructive Surgical Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Vittoria Espeli, MD and Cristina Mangas, MD, PhD, Istituto Oncologico Svizzera Italiana, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland; Pietro Quaglino, MD; Simone Ribero, MD, PhD; and Paolo Broganelli, MD, University Hospital of Turin, Turin, Italy; Giovanni Pellacani, MD, University Hospital of Modena, Modena, Italy; Caterina Longo, MD, Arcispedale S. Maria Nuova, Reggio Emilia, Italy; Corrado Del Forno, MD, University Hospital of Pavia, Pavia, Italy; Lorenzo Borgognoni, MD and Serena Sestini, MD, Ospedale S. Maria Annunziata, Tuscan Cancer Institute, Florence, Italy; Nicola Pimpinelli, MD, PhD and Sara Fortunato, MD, Division of Dermatology, University of Florence, Florence, Italy; Alessandra Chiarugi, MD and Paolo Nardini, MD, Institute for Cancer Research and Prevention, Florence, Italy; Elena Morittu, PhD and Antonio Florita, PhD, Scientific Director's Office, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Mara Cossa, MD, PhD; Barbara Valeri, MD; Massimo Milione, MD, PhD; and Giancarlo Pruneri, MD, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; Odysseas Zoras, MD, PhD, University Hospital of Heraklion, Heraklion, Greece; Andrea Anichini, PhD and Roberta Mortarini, PhD, Immunobiology of Human Cancers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and Mario Santinami, MD, Melanoma and Sarcoma Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

出版信息

J Clin Oncol. 2020 Sep 20;38(27):3238-3240. doi: 10.1200/JCO.20.01460. Epub 2020 Jul 23.

DOI:10.1200/JCO.20.01460
PMID:32701413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7499609/
Abstract
摘要